Skip to main content
Erschienen in: Digestive Diseases and Sciences 7/2016

23.05.2016 | Rapid Communications

Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)

verfasst von: Anne C. Moorman, Xin Tong, Philip R. Spradling, Loralee B. Rupp, Stuart C. Gordon, Mei Lu, Eyasu H. Teshale, Joseph A. Boscarino, Connie M. Trinacty, Mark A. Schmidt, Fujie Xu, Scott D. Holmberg

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Guidelines for the treatment of HCV-infected persons were updated in August 2015 with new recommendations for patients with renal impairment. Treatment is imperative for patients with severe, renal-associated extrahepatic manifestations of HCV infection.

Aims

We sought to describe the prevalence of these conditions among current HCV-infected patients in a population-based prospective, observational cohort study at four large US health systems.

Methods

Data from cohort patients with chronic HCV infection during 2012 were analyzed for the period from 2006 to 2013. We determined the prevalence of mild to moderately impaired renal function defined as having the most recent estimated glomerular filtration rate [eGFR] ≤ 80 ml/min/1.73 m2, with severe impairment defined as eGFR < 30 ml/min/1.73 m2, based on the treatment guidelines. Prevalence of extrahepatic conditions was ascertained using ICD9-codes.

Results

Among 5772 persons, the prevalence of eGFR ≤ 80 was 33 % and eGFR < 30 was 2 %, including among patients with hepatic fibrosis. Diagnosed extrahepatic renal manifestations were rare: vasculitis- 0.2 %, nephrotic syndrome- 0.3 %, and cryoglobulinemia- 0.9 %.

Conclusions

While the prevalence of severe renal impairment and diagnosed extrahepatic manifestations was low, mild-to-moderate renal impairment was common in HCV patients, including those with advanced liver fibrosis for whom the need for treatment is urgent.
Literatur
2.
Zurück zum Zitat Saxena V, Koraishy F, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S267. Saxena V, Koraishy F, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S267.
3.
Zurück zum Zitat Pockros P, Reddy K, Mantry P, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal-disease: the Ruby-I Study. International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S257.CrossRef Pockros P, Reddy K, Mantry P, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal-disease: the Ruby-I Study. International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22–26, 2015. J Hepatol. 2015;62:S257.CrossRef
4.
Zurück zum Zitat Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.CrossRefPubMed Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.CrossRefPubMed
5.
Zurück zum Zitat Terrault N. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.CrossRefPubMed Terrault N. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.CrossRefPubMed
6.
Zurück zum Zitat Finelli L, Miller J, Tokars J, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semi Dial. 2005;18:52–61. Finelli L, Miller J, Tokars J, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semi Dial. 2005;18:52–61.
8.
Zurück zum Zitat Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–657.CrossRefPubMed Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–657.CrossRefPubMed
9.
Zurück zum Zitat Butt AA, Skanderson M, McGinnis KA, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat. 2007;14:688–696.PubMed Butt AA, Skanderson M, McGinnis KA, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat. 2007;14:688–696.PubMed
10.
Zurück zum Zitat Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168–1174.CrossRefPubMed Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168–1174.CrossRefPubMed
11.
Zurück zum Zitat Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285–290.CrossRefPubMed Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285–290.CrossRefPubMed
12.
Zurück zum Zitat Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840–1848.CrossRefPubMed Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840–1848.CrossRefPubMed
14.
Zurück zum Zitat Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. J Hepatol. 2015;63:822–828. Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. J Hepatol. 2015;63:822–828.
15.
Zurück zum Zitat Gonzaelz HC, Lamerato L, Rogers CG, Gordon SC. Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci. 2015;60:1820–1824.CrossRef Gonzaelz HC, Lamerato L, Rogers CG, Gordon SC. Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci. 2015;60:1820–1824.CrossRef
16.
Zurück zum Zitat Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207.CrossRefPubMed Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207.CrossRefPubMed
17.
Zurück zum Zitat Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369–378.CrossRefPubMed Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369–378.CrossRefPubMed
18.
Zurück zum Zitat Espinosa M, Martin-Malo A, varez de Lara M, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001;16:1669–1674. Espinosa M, Martin-Malo A, varez de Lara M, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001;16:1669–1674.
19.
Zurück zum Zitat Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206–2220.CrossRefPubMed Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206–2220.CrossRefPubMed
20.
Zurück zum Zitat Molnar M, Alhourani H, Wall B, et al. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015. doi:10.1002/hep.27664. Molnar M, Alhourani H, Wall B, et al. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015. doi:10.​1002/​hep.​27664.
21.
Zurück zum Zitat Butt AA, Yan P, Lo Re V, et al. Study Team. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178–185.CrossRefPubMed Butt AA, Yan P, Lo Re V, et al. Study Team. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178–185.CrossRefPubMed
22.
Zurück zum Zitat Kidney Disease Improving Global Outcomes (KDIGO) Task Force. 2012 Classification of chronic kidney disease. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3:x, 15–18. Kidney Disease Improving Global Outcomes (KDIGO) Task Force. 2012 Classification of chronic kidney disease. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3:x, 15–18.
23.
Zurück zum Zitat Moorman A, Gordon S, Rupp L, et al. for the CHeCS Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;56:40–50. Moorman A, Gordon S, Rupp L, et al. for the CHeCS Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;56:40–50.
24.
Zurück zum Zitat Holmberg S, Lu M, Rupp LB, et al. Use of non-invasive serum markers for staging hepatitis C virus (HCV) in the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;57:240–246.CrossRefPubMed Holmberg S, Lu M, Rupp LB, et al. Use of non-invasive serum markers for staging hepatitis C virus (HCV) in the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2013;57:240–246.CrossRefPubMed
25.
Zurück zum Zitat Li J, Gordon SC, Rupp LB, et al. Lu M; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930–937.CrossRefPubMed Li J, Gordon SC, Rupp LB, et al. Lu M; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930–937.CrossRefPubMed
27.
Zurück zum Zitat Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate Glomerular filtration rate. Ann Intern Med. 2009;150:604–612.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate Glomerular filtration rate. Ann Intern Med. 2009;150:604–612.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Tong X, Spradling P. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004–2011. J Viral Hepat. 2015;22:906–913.CrossRefPubMed Tong X, Spradling P. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004–2011. J Viral Hepat. 2015;22:906–913.CrossRefPubMed
Metadaten
Titel
Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)
verfasst von
Anne C. Moorman
Xin Tong
Philip R. Spradling
Loralee B. Rupp
Stuart C. Gordon
Mei Lu
Eyasu H. Teshale
Joseph A. Boscarino
Connie M. Trinacty
Mark A. Schmidt
Fujie Xu
Scott D. Holmberg
Publikationsdatum
23.05.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4199-x

Weitere Artikel der Ausgabe 7/2016

Digestive Diseases and Sciences 7/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.